Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

OnlyRx vs Vaylen

Two GLP-1 desks, one scoreboard. We put OnlyRx and Vaylen head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 293 · Grade C

OnlyRx

Visit OnlyRx Full brief →
vs
Higher Brief ScoreNo. 15 · Grade B+

Vaylen

Visit Vaylen Full brief →

The verdict

Vaylen takes this head-to-head.

Vaylen scores 87 to 62 on our six-factor Brief Score — A full-service, LegitScript-certified desk pairing brand access and an oral route with nationwide reach at a fair mid price.

That doesn't make OnlyRx a bad call — it's best for readers who want compounded glp-1 in oral-tablet and injection with named prescribers. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
48
85
Supply Reliability
61
87
Transparency
72
87
Access Breadth
62
92
Clinical Oversight
72
88
Track Record
63
82
OnlyRxBrief Score 62 · 87Vaylen

Price, coverage & the tracker

OnlyRxVaylen
Brief Score62/100 (C)87/100 (B+)
SemaglutideFrom $179/mo (starting dose, promotional rate, compounded)$179/mo
TirzepatideFrom $249/mo (starting dose, compounded)$239/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessYesYes
Oral / sublingualYesYes
On the trackerNewnew to the tracker, no prior readingStableprice stable

OnlyRx: New to the tracker on 1 August 2026. The published line reads From $179/mo (starting dose, promotional rate, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Vaylen: $179 sema / $239 tirz; brand + oral + LegitScript across all 50 states.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.